Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
David Paez, Laia Paré, Iñigo Espinosa, Juliana Salazar, Elisabeth del Rio, Agustí Barnadas, Eugenio Marcuello, Montserrat Baiget
Dive into the research topics of 'Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?'. Together they form a unique fingerprint.